Dose-escalation, Repeated and Single Oral Dosing Study
Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral Dosing Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Temanogrel Co-administered With Aspirin and Clopidogrel
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
- To investigate pharmacokinetic and pharmacodynamic characteristics of Temanogrel when orally co-administered with Aspirin and/or Clopidogrel in healthy subject. a person determined to be suitable for the purpose of this clinical trial by investigator with consideration for the age and the health status of a volunteer is selected
- Assess the safety of Temanogrel when orally co-administered with Aspirin and/or Clopidogrel in healthy subjects.
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- La phase 1
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- a healthy adult between 20 and 45 years old at the time of visit for screening
- a person who is able to give written consent
- a person between 50 and 85 kg at the time of visit for screening
- a woman who is negative on a serum hCG test at the time of visit and the day before a trial, and who is not nursing, a woman who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, or who had a contraceptive operation no later than 120 days before visit for screening, or who is menopausal, a man who had a contraceptive operation no later than 120 days before visit for screening, or who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, and also agree not to donate sperm
- a person more than hemoglobin 12 g/dL at the time of screening (a woman more than hemoglobin 11 g/dL)
- a person whose vital signs were in the normal range at the time of visit for screening, or who is medically determined not to be clinically significant by an investigator
Exclusion Criteria:
- a person with the medical history of gastric ulcer, duodenal ulcer or esophageal ulcer within 90 days from the time of visit for screening
- a person with the medical history of gastrointestinal diseases(e.g. Crohn's disease, ulcerative colitis, etc.) or surgery(excluding uncomplicated appendectomy or herniotomy) affecting the absorption of a clinical trial drug
- a person with the medical history of blood coagulation disorder or hemorrhagic diseases, or with clinically significant abnormal findings decided by a investigator on blood coagulation test at the time of screening
- a woman with the medical history of dysfunctional uterine bleeding within a year from the time of visit for screening
- a person with the medical history of epilepsy or convulsion
- a person with the medical history of internal organ transplant
- a person expected to be hard to complete a clinical trial because of surgery or medical procedures planned within a clinical trial period
- a person with the medical history of clinically significant new diseases within 30 days from the time of visit for screening according to investigator's decision
- a person with hypersensitivity reaction to a drug or gelatin, or the medical history of clinically significant hypersensitivity reaction
- a person with the history of drug abuse, or with a positive reaction to a drug possible to be abused on urine drug screening
- a person with the medical history of alcohol abuse within two years from the time of visit for screening
- a person who is a smoker, or with a positive reaction on a urine nicotine test conducted at the time of visit for screening
- a person who donated whole blood within 60 days or constituents of blood within 30 days, or received a blood transfusion within 30 days from the time of visit for screening
- a person taking other clinical trial drugs within 90 days from the time of visit for screening
- a person taking a prescription drug within 30 days, or a contraindicated drug or oriental medicine within 14 days from the time of visit for screening
- a person with a positive reaction to a serum test(hepatitis B test, hepatitis C test, HIV test, syphilis test)
- a person with hepatic enzymes(AST, ALT) more than 2.5 times of the reference upper limit(UNL) or total bilirubin more than 1.5 times of the reference upper limit(UNL) or creatinine more than 1.25 times of the reference upper limit(UNL)
- a person expected to be hard to complete a clinical trial due to physical or mental status according to investigator's medical decision at the time of visit for screening
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Dépistage
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: APD791 10mg single dose
|
Temanogrel
Autres noms:
|
|
Expérimental: APD791 20mg single dose
|
Temanogrel
Autres noms:
|
|
Expérimental: APD791 40mg single dose
|
Temanogrel
Autres noms:
|
|
Expérimental: APD791 10mg
APD791 10mg single dose + Aspirin + Clopidogrel
|
Clopidogrel
Autres noms:
Temanogrel
Autres noms:
Aspirine
Autres noms:
|
|
Expérimental: APD791 20mg
APD791 20mg single dose + Aspirin + Clopidogrel
|
Clopidogrel
Autres noms:
Temanogrel
Autres noms:
Aspirine
Autres noms:
|
|
Expérimental: APD791 40mg
APD791 40mg single dose + Aspirin + Clopidogrel
|
Clopidogrel
Autres noms:
Temanogrel
Autres noms:
Aspirine
Autres noms:
|
|
Expérimental: APD791 80mg
APD791 80mg single dose + Aspirin + Clopidogrel
|
Clopidogrel
Autres noms:
Temanogrel
Autres noms:
Aspirine
Autres noms:
|
|
Expérimental: APD791 160mg
APD791 160mg single dose + Aspirin + Clopidogrel
|
Clopidogrel
Autres noms:
Temanogrel
Autres noms:
Aspirine
Autres noms:
|
|
Expérimental: APD791 240mg
APD791 240mg single dose + Aspirin + Clopidogrel
|
Clopidogrel
Autres noms:
Temanogrel
Autres noms:
Aspirine
Autres noms:
|
|
Expérimental: APD791 320mg
APD791 320mg single dose + Aspirin + Clopidogrel
|
Clopidogrel
Autres noms:
Temanogrel
Autres noms:
Aspirine
Autres noms:
|
|
Comparateur placebo: APD791 Placebo
APD791 placebo for single dose + Aspirin + Clopidogrel
|
Clopidogrel
Autres noms:
Temanogrel
Autres noms:
Aspirine
Autres noms:
Placebo for APD791
Autres noms:
|
|
Expérimental: APD791 2mg MD
APD791 2mg multiple dose + Aspirin + Clopidogrel
|
Clopidogrel
Autres noms:
Temanogrel
Autres noms:
Aspirine
Autres noms:
|
|
Expérimental: APD791 5mg MD
APD791 5mg multiple dose + Aspirin + Clopidogrel
|
Clopidogrel
Autres noms:
Temanogrel
Autres noms:
Aspirine
Autres noms:
|
|
Expérimental: APD791 10mg MD
APD791 10mg multiple dose + Aspirin + Clopidogrel
|
Clopidogrel
Autres noms:
Temanogrel
Autres noms:
Aspirine
Autres noms:
|
|
Expérimental: APD791 20mg MD
APD791 placebo for multiple dose + Aspirin + Clopidogrel
|
Clopidogrel
Autres noms:
Temanogrel
Autres noms:
Aspirine
Autres noms:
|
|
Comparateur placebo: APD791 placebo MD
APD791 placebo for multiple dose + Aspirin + Clopidogrel
|
Clopidogrel
Autres noms:
Temanogrel
Autres noms:
Aspirine
Autres noms:
Placebo for APD791
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Pharmacokinetics-Cmax
Délai: Day1, Day2, Day3, Day4, Day 7
|
Day1, Day2, Day3, Day4, Day 7
|
|
Pharmacokinetics-Tmax
Délai: Day1, Day2, Day3, Day4, Day 7
|
Day1, Day2, Day3, Day4, Day 7
|
|
Pharmacodynamics-% inhibition of serotonin-stimulated platelet aggregation
Délai: Day1, Day2, Day4, Day7, Day 8
|
Day1, Day2, Day4, Day7, Day 8
|
|
Pharmacodynamics-change of serotonin-stimulated platelet aggregation
Délai: Day1, Day4, Day7
|
Day1, Day4, Day7
|
|
Pharmacodynamics-% inhibition of TRAP-induced platelet aggregation
Délai: Day1, Day4, Day7 of every dose for mutiple dose group and first day for single dose group.
|
Day1, Day4, Day7 of every dose for mutiple dose group and first day for single dose group.
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
adverse event monitoring
Délai: up to post-study visit(8day±2)
|
up to post-study visit(8day±2)
|
|
physical examination
Délai: up to post-study visit(8day±2)
|
up to post-study visit(8day±2)
|
|
vital signs
Délai: up to post-study visit(8day±2)
|
up to post-study visit(8day±2)
|
|
ECG
Délai: up to post-study visit(8day±2)
|
up to post-study visit(8day±2)
|
|
laboratory test
Délai: up to post-study visit(8day±2)
|
up to post-study visit(8day±2)
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Chercheur principal: Gyunseop Bae, M.D., Asan Medical Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Ischémie myocardique
- Maladies cardiaques
- Maladies cardiovasculaires
- Maladies vasculaires
- Syndrome coronarien aigu
- Effets physiologiques des médicaments
- Agents neurotransmetteurs
- Mécanismes moléculaires de l'action pharmacologique
- Agents du système nerveux périphérique
- Inhibiteurs d'enzymes
- Analgésiques
- Agents du système sensoriel
- Agents anti-inflammatoires non stéroïdiens
- Analgésiques, non narcotiques
- Agents anti-inflammatoires
- Agents antirhumatismaux
- Agents fibrinolytiques
- Agents modulateurs de fibrine
- Inhibiteurs de l'agrégation plaquettaire
- Inhibiteurs de la cyclooxygénase
- Antipyrétiques
- Antagonistes des récepteurs purinergiques P2Y
- Antagonistes des récepteurs purinergiques P2
- Antagonistes purinergiques
- Agents purinergiques
- Agents de sérotonine
- Antagonistes des récepteurs de la sérotonine 5-HT2
- Antagonistes de la sérotonine
- Aspirine
- Clopidogrel
- APD791
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- ID-TMG-102
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .